Phase II study of XELIRI and High-dose bevacizumab as second-line therapy in patients with metastatic colorectal cancer
收藏NIAID Data Ecosystem2026-03-07 收录
官方服务：
资源简介：
Interventions: XELIRI plus bevacizumab therapy Bevacizumab 10mg/kg day1 Irinotecan 150mg/m2 day1 Capecitabin 2,000mg/m2/day day1-8 Primary outcome(s): Progression Free Survival Study Design: Single arm Non-randomized
创建时间：
2012-07-15
